Nevertheless, the subgroup analysis demonstrated that EBV-associated GC with ARID1A-lost/heterogeneous expression exhibited more aggressive behavior (P = 0.016), corroborated by the meta-analysis revealing that ARID1A loss was associated with poor overall survival in EBV-associated GC > 5% subgroup (HR 1.59, 95% CI 1.18–2.15) [6]. Here, ARID1A is linked to gastric cancer.